← Scoopfeeds — Intelligent news, curated.
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda
business

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda

Yahoo Finance · May 18, 2026, 11:42 AM · Also reported by 2 other sources

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Merck’s endometrial cancer drug meets trial goals Investing.com Truist cuts Regeneron stock price target on LAG-3 trial miss

More in business

MarketWatch
These 10 tech stocks have been models of consistency for a decade — none are chip stocks
CoinDesk
Vitalik Buterin says AI 'formal verification' could actually make crypto much more secure
CNBC
State judge blocks evidence from Luigi Mangione backpack in UnitedHealthcare CEO murder case
Bloomberg Markets
Blue Owl Fund Returns to Market With $400 Million Bond Offering
CNBC
Homebuilder sentiment improves on late spring surge in demand
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop